On May 23, 2025 Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, reported that it will participate in four upcoming investor conferences in May and June (Press release, Allogene, MAY 23, 2025, View Source [SID1234653354]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TD Cowen’s 6th Annual Oncology Innovation Summit: Insights for ASCO (Free ASCO Whitepaper) & EHA (Free EHA Whitepaper)
Tuesday, May 27
9:30AM PT/12:30PM ET

Jefferies Global Healthcare Conference
Wednesday, June 4
1:55PM PT/4:55PM ET

Goldman Sachs 46th Annual Global Healthcare Conference
Tuesday, June 10
5:00AM PT/8:00AM ET

Oppenheimer Innovators in I&I Summit
Wednesday, June 25
9:45AM PT/12:45PM ET

Any available webcasts will be posted to the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company’s website for approximately 30 days.